The Asian Myeloid Working Group was initiated in 2016 when a small group of haematologists with special interest in acute myeloid leukaemia (AML), acute promyelocytic leukaemia (APL), myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN) from Hong Kong, Singapore, Malaysia and Thailand convened to discuss the recent developments and unmet need in terms of research and development in the region.
Thereafter, in 2017, the first project across Asia, titled “Clinical and Genomic Registry of Myelodysplastic Syndrome and Secondary Acute Myeloid in Asia” came to fruition.
From 2019 to present, major developments included the formation of the Acute Promyelocytic Leukaemia Asian Consortium (APL-AC), the first consensus guideline development for the management of myeloproliferative neoplasm in Asia, and the initiation of the multicentre oral arsenic trioxide-based induction for APL.
Despite the COVID-19 pandemic, members of the group remained actively engaged via virtual platforms. To-date, the AWMG has more than 20 members across 7 regions in Asia. In March 2021, the AMWG was registered as a formal legal entity and non-profit organization under the Government of the Hong Kong Special Administrative Region (HKSAR).
